Cefotiam
A second-generation parenteral cephalosporin antibiotic with activity against gram-positive and gram-negative organisms, used in Japan and some European countries for respiratory, urinary, and surgical prophylaxis indications. It does not contain the N-methylthiotetrazole side chain and therefore lacks the alcohol interaction seen with some related drugs. It is not widely available in North America.
Peso Molecular
525,6000 g/mol
LogP
-2,40
TPSA
251,00 Ų
Regra dos 5 de Lipinski
Reprovado
Mecanismo de Ação
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1
InChI
InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1
Molecular Formula
C18H23N9O4S3
HBD / HBA
3 / 13
Ligações Rotacionáveis
10
Átomos Pesados
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A second-generation parenteral cephalosporin antibiotic with activity against gram-positive and gram-negative organisms, used in Japan and some European countries for respiratory, urinary, and surgical prophylaxis indications. It does not contain the N-methylthiotetrazole side chain and therefore lacks the alcohol interaction seen with some related drugs. It is not widely available in North America.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefotiam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1296. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 43708. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefotiam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefotiam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefotiam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefotiam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefotiam"></drugfyi-drug>